Analysts Set Option Care Health, Inc. (NASDAQ:OPCH) PT at $29.86

Option Care Health, Inc. (NASDAQ:OPCH) has received an average rating of “Moderate Buy” from the seven ratings firms that are covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $29.86.

Several equities analysts have recently issued reports on the stock. Jefferies Financial Group lowered shares of Option Care Health from a “buy” rating to a “hold” rating and lowered their target price for the company from $38.00 to $26.00 in a report on Thursday, October 31st. UBS Group began coverage on Option Care Health in a report on Thursday, December 5th. They issued a “neutral” rating and a $26.00 target price on the stock. Bank of America upgraded Option Care Health from a “neutral” rating to a “buy” rating and raised their price target for the company from $26.00 to $33.00 in a report on Monday, January 13th. JMP Securities reiterated a “market outperform” rating and issued a $30.00 price target (down previously from $31.00) on shares of Option Care Health in a research note on Friday, January 10th. Finally, Barrington Research raised their price objective on shares of Option Care Health from $32.00 to $33.00 and gave the company an “outperform” rating in a research note on Tuesday, January 14th.

Insider Buying and Selling at Option Care Health

In related news, Director Harry M. Jansen Kraemer, Jr. bought 43,000 shares of the firm’s stock in a transaction on Friday, November 8th. The stock was acquired at an average cost of $22.54 per share, for a total transaction of $969,220.00. Following the purchase, the director now owns 326,334 shares in the company, valued at approximately $7,355,568.36. This represents a 15.18 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.64% of the company’s stock.

Hedge Funds Weigh In On Option Care Health

Several institutional investors have recently made changes to their positions in the business. Westfield Capital Management Co. LP lifted its position in Option Care Health by 10.2% during the third quarter. Westfield Capital Management Co. LP now owns 6,492,152 shares of the company’s stock valued at $203,204,000 after purchasing an additional 599,589 shares in the last quarter. Global Alpha Capital Management Ltd. lifted its position in shares of Option Care Health by 108.3% during the 3rd quarter. Global Alpha Capital Management Ltd. now owns 49,818 shares of the company’s stock valued at $1,559,000 after buying an additional 25,905 shares in the last quarter. Graypoint LLC bought a new position in shares of Option Care Health during the 4th quarter valued at approximately $1,161,000. Victory Capital Management Inc. increased its holdings in Option Care Health by 4,432.8% in the 3rd quarter. Victory Capital Management Inc. now owns 1,621,593 shares of the company’s stock worth $50,756,000 after acquiring an additional 1,585,818 shares in the last quarter. Finally, Barclays PLC raised its stake in Option Care Health by 180.1% during the 3rd quarter. Barclays PLC now owns 310,194 shares of the company’s stock worth $9,708,000 after acquiring an additional 199,454 shares during the period. Institutional investors own 98.05% of the company’s stock.

Option Care Health Trading Down 0.5 %

Shares of NASDAQ OPCH opened at $29.16 on Friday. Option Care Health has a 1 year low of $21.39 and a 1 year high of $34.63. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.73 and a quick ratio of 1.32. The firm has a 50-day moving average of $23.70 and a 200 day moving average of $27.74. The stock has a market cap of $4.96 billion, a P/E ratio of 24.50, a price-to-earnings-growth ratio of 2.44 and a beta of 1.31.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.